New nanomaterial passes the blood-brain barrier to reduce damaging inflammation after the most common form of stroke. When ...

Roger E Susi, CEO at iRadimed (NASDAQ: IRMD ), reported an insider sell on January 13, according to a new SEC filing. What ...

ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per ...

Roger E. Susi said, "But first, yes, we anticipate a price increase of 10% to 14%." Management targeted delivering more than 2,000 annual pump channel sales in the U.S, representing a step-change in ...

We recently published 10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade. IRadimed Corporation (NASDAQ:IRMD) is among the best small-cap stocks to buy ...

Total Revenue-- $21.2 million for the third quarter of 2025, up 16%, driven by MRI compatible IV infusion pump and monitoring system growth. Gross Profit and Margin-- $16.4 million at 78% margin for ...

Pump shipments again led performance in the quarter as our 3860 MRI IV pump grew another 20% year-over-year in Q3. Our MR monitor sales have also continued to impress. I am also pleased to report that ...

IRadimed Corporation (NASDAQ:IRMD) Q3 2025 Earnings Call Transcript November 3, 2025 IRadimed Corporation beats earnings expectations. Reported EPS is $0.47, expectations were $0.43. Operator: Welcome ...

Management raised Q4 2025 revenue guidance to $21.4 million to $22.4 million and GAAP diluted EPS guidance to $0.43 to $0.47, with non-GAAP diluted EPS of $0.47 to $0.50. For full year 2025, guidance ...